Locations
Conditions
Treatments
Institutions
Resources
For researchers
About us
Clinical trials
First-Line Ipilimumab Plus Nivolumab and Nogapendekin Alfa Inbakicept (N-803) in Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer
Apply
Nivolumab, Ipilimumab, IL-15
First-Line Ipilimumab Plus Nivolumab and Nogapendekin Alfa Inbakicept (N-803) in Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer
Basic information
Step 1/5
Provide your basic information
Age
ZIP code
Back
Next step